Trials / Recruiting
RecruitingNCT06725719
Translocator Protein PET/CT in Various TSPO-Related Disease
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Tianjin Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
To evaluate the potential usefulness of 18F-DPA714/FDPA positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various TSPO-related disease patients.
Detailed description
Subjects with various Tau-related disease patients underwent 18F-DPA714/FDPA PET/CT either for an initial assessment or for recurrence detection. Lesions uptake was quantified by the maximum standard uptake value (SUVmax). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of 18F-DPA714/FDPA PET/CT were calculated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | 18F-DPA714/FDPA | Each subject receive a single intravenous injection of 18F-DPA714/FDPA, and undergo PET/CT or MRI imaging within the specificed time. |
Timeline
- Start date
- 2018-11-01
- Primary completion
- 2027-12-01
- Completion
- 2027-12-01
- First posted
- 2024-12-10
- Last updated
- 2025-02-11
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06725719. Inclusion in this directory is not an endorsement.